

Response after Final Rejection
USSN 10/603,503

Attorney Docket R0232I-CNT

In the Claims:

23. (Currently amended) A compound that is non-crystalline 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)-methoxy-3-hydroxy-1-propanyl-L-valinate hydrochloride.

24. (Previously presented) An antiviral pharmaceutical composition comprising the compound of Claim 23 and a pharmaceutically acceptable excipient.

25. (Previously presented) A method of treating an animal afflicted with a virus selected from herpes simplex virus, herpes types 1, 2 and 6, varicella Zoster, Epstein-Barr virus, hepatitis B and cytomegalovirus, comprising administering a therapeutically acceptable amount of the compound of Claim 23 to the animal.

26. (Previously presented) The method of Claim 25 where the virus is cytomegalovirus.

27. (Previously presented) The method of Claim 26 where the compound is administered orally.

28. (Previously presented) The method of Claim 25 where the animal is a human.

29. Canceled.